Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#3672 Impact of everolimus starting dose on antiproliferative efficacy in patients with neuroendocrine tumors – Experiences from a tertiary referral center

Introduction: Everolimus is approved at a full dose of 10 mg daily for the treatment of advanced neuroendocrine tumors (NETs) but associated with relevant toxicities. Hence dose reductions are a frequent event in clinical practice.

Conference:

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Melhorn P, Macheiner S, Wolff L, Kretschmer-Chott E,

Keywords: everolimus, dose reduction, advanced NET, systemic therapy, medical oncology,

#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,

#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Berardi R

Authors: Berardi R, Torniai M, Pusceddu S, Spada F, Brizzi M,

Keywords: pNET, dose intensity, targeted therapy, everolimus, cumulative dose,